Study to Treat Major Depressive Disorder (MDD) With a New Medication
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the antidepressant effects of Ezogabine in major
depressive disorder (MDD). The investigators also aim to determine the safety and
tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive
symptoms will be significantly decreased following an 8-week treatment period of the
medication compared to baseline.